[In vivo effects of high density lipoprotein rich serum fractions (HDLF) in the human. 2. Effect of repeated HDLF infusions on atherogenic risk factors and arteriosclerotic vascular changes in patients with and without hyperlipoproteinemia].
10 patients with hyperlipoproteinaemia and 4 normolipaemic smokers with angiographically proved arteriosclerosis of different degrees of severity were infused in 2-week intervals 100 ml HDL-rich Cohn-IV-1 fractions each. After the infusion for 5 days essential phospholipids were injected and a permanent medication with cholestyramin and a choleretic drug were prescribed. In the patients with HLP increases of concentration, decreases of concentration, constancy of the plasma lipids and apoproteins independent of the phaenotype of the HLP as well as an improvement of the state of the antioxidant state were observed. In 6 of 10 patients in reproducible vascular areas regressions of athero- und arteriosclerotic findings could be made evident. Progressions were not observed also in extremely changed arteries in contrast to the normolipaemic smokers and the patients of the control group.
Kuklinski
B
B
Klinik für Innere Medizin, Karl-Marx-Universität Leipzig.
Parfionov
A S
AS
Rühlmann
C
C
Zimmermann
R
R
Herrmann
W
W
Richter
V
V
Köhler
H
H
Grossmann
K D
KD
Peters
H J
HJ
Duck
H J
HJ
D001161:Arteriosclerosis / Q000097:blood / Q000628:therapy*; D008076:Cholesterol, HDL / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000628:therapy*; D008055:Lipids / Q000097:blood; D008075:Lipoproteins, HDL / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
D008076:Cholesterol, HDL; D008055:Lipids; D008075:Lipoproteins, HDL
In-vivo-Wirkungen High-Density-lipoprotein-reicher Serumfraktionen (HDLF) beim Menschen. 2. Mitteilung: Einfluss wiederholter HDLF-Infusionen auf atherogene Risikofaktoren sowie auf arteriosklerotische Gefässveränderungen bei Patienten mit und ohne Hyperlipoproteinämie.